Novo Nordisk(US:NVO) GLP1减重宝典·2025-09-11 08:15Core Viewpoint - Novo Nordisk's innovative drug amycretin shows significant weight loss results in clinical trials, indicating a promising new treatment option for obesity and type 2 diabetes patients [6][7][9]. Group 1: Clinical Trial Results - The clinical trial results for amycretin were presented at the 85th American Diabetes Association (ADA) Scientific Sessions, highlighting its effectiveness in weight reduction among overweight or obese individuals [6][7]. - In a 36-week treatment period, the 60 mg dose group experienced an average weight loss of 24.3%, compared to a 1.1% increase in the placebo group [7]. - The 20 mg dose group achieved a 22.0% weight loss, while the 5 mg and 1.25 mg groups showed weight reductions of 16.2% and 9.7%, respectively, with all groups demonstrating no plateau in weight loss by the end of the treatment [7]. Group 2: Safety and Tolerability - Amycretin exhibited excellent tolerability at the 60 mg dose, with safety profiles consistent with existing GLP-1 and incretin receptor agonists [7]. - Adverse reactions were primarily gastrointestinal and showed a dose-dependent increase, but most were mild to moderate and resolved by the end of the trial [7][8]. - The oral formulation of amycretin also demonstrated significant weight loss, with participants losing 10.4% and 13.1% of their body weight in different dosing regimens, compared to a mere 1.2% in the placebo group [8]. Group 3: Development and Future Prospects - Amycretin is a long-acting single-molecule formulation that activates both GLP-1 and incretin receptors, providing a synergistic effect on appetite regulation [9]. - Novo Nordisk is accelerating the development of both subcutaneous and oral forms of amycretin, with ongoing phase 3 clinical trials to evaluate its potential as a next-generation weight management solution [9].